Novo Nordisk Completes Landmark Diabetes Affordability Project
Diabetes is a serious chronic disease with a prevalence rate of 10.2 percent in adults in Thailand, and the number of people living with diabetes rose by 300,000 in 2023. To compound the issue, there are many unmet needs as almost 14 percent of those diagnosed are not being treated. The three-year Affordability Project therefore focused on enhancing access to quality care, improving diagnostic measures, and training healthcare professionals (HCPs) across the nation.
The project's highlights include:
Screening success: The project has screened 53,000 individuals across 13 health zones in 21 provinces, exceeding initial targets and broadening diabetes detection efforts in underserved populations.
HCPs training: A total of 7,000 HCPs were trained, aimed at adopting effective diabetes management practices. This training reached more than 2,200 hospitals nationwide, including practical workshops tailored to enhance patient care with more than 15,000 patients who received care from trained HCPs to help control their average blood sugar (HbA1c) levels.
Glucose Control Initiative: The intensive glucose control programme enrolled 5,000 people living with diabetes, achieving remarkable results. Almost 70 percent of them reduced their HbA1c levels in every visit, with 28 percent reaching their treatment goals.
Dr Taweesilp Visanuyothin, MD, Director-General of the Department of Medical Services, Ministry of Public Health, stated: 'Healthcare professionals have always been central to the effective treatment of diseases that require integrated care, such as diabetes. The Affordability Project is an example of how the public sector can collaborate with our partners in the private sector to enhance expertise for better patient care.'
Dr Jinda Rojanamatin, MD, Director of Rajavithi Hospital, remarked: 'Rajavithi Hospital has been the primary institution to implement the project over the past three years. With our resources and expertise, the hospital has integrated the treatments for cardiovascular diseases and other non-communicable diseases (NCDs), including diabetes.'
Ms Selina Christodoulakis, Director of Market Access and Public Affairs at Novo Nordisk Thailand, emphasised the rationale behind the project: 'Through the Affordability Project, we have made significant strides in making diabetes care more accessible and effective for the Thai population. By partnering with stakeholders across health systems in public sector to build integrated diabetes solutions that support healthcare professionals and improve the lives of people living with diabetes, we are collectively driving change for better health outcomes in Thailand.'
With diabetes estimated to cost the Thai economy more than 375 billion THB, accounting for over 2.2 percent of the Thai GDP, the impact of the project transcends improved health outcomes. Effective blood glucose control has been linked to a reduction in severe complications related to diabetes, which can ultimately lead to substantial long-term savings in Thai healthcare costs.
The event also featured the Cardio-Renal-Metabolic Clinic (CRM) at Rajavithi Hospital, aimed at elevating the standards of integrated care for NCDs, including the complications of obesity, diabetes, and other cardiovascular diseases.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bangkok Post
19 hours ago
- Bangkok Post
Hospital explains service hiatus for Cambodians
Sunpasitthiprasong Hospital, Ubon Ratchathani's provincial state-run hospital, issued a formal statement yesterday to clarify its controversial move to temporarily suspend certain services for Cambodian nationals. The decision follows heightened tensions along the Thai-Cambodian border and has drawn sharp criticism from opposition lawmakers. In a memorandum issued Wednesday, hospital director Dr Monchai Wiwattanasitthiphong cited national security concerns stemming from the unrest near the frontier. The directive announced several measures, including the suspension of new Cambodian patient admissions (except in emergencies), cancellation of medicine pickups on their behalf, and a temporary halt to Cambodian-language interpreter services. The memo also stated that Cambodian patients currently admitted would be restricted to clearly defined areas within the hospital for security reasons. The measures took effect yesterday and will remain in place until August 10. Following public backlash, the hospital yesterday released a clarification, insisting the policy was based on humanitarian principles and public safety. It stressed that Cambodian patients already admitted would continue to receive appropriate and non-discriminatory care. However, the hospital said certain adjustments to non-urgent services were necessary due to logistical challenges, including transport disruptions and a backlog of uncollected prescriptions. While general admissions are restricted, the hospital confirmed it would still treat Cambodian patients in emergency cases. As part of its temporary restructuring, the hospital has also postponed non-urgent surgeries and suspended its specialised out-of-hours SMC Premium Clinic to prioritise core medical services.
Bangkok Post
20 hours ago
- Bangkok Post
Unprejudiced healthcare
It's a universal principle that hospitals must be free of discrimination. Unfortunately, this seems not to be the case for Ubon Ratchathani-based Sunpasitthiprasong Hospital, which has decided not to provide any medical services to Cambodians. This is discrimination and a breach of human rights and humanitarian principles. In an official note issued July 30, the hospital said it has closed its special medical clinic (SMC) to Cambodians, citing its heavy case load. This dubiously explained policy started yesterday and will run until Aug 10. The hospital will also stop hiring Khmer-speaking interpreters and will no longer provide accommodation for a group of volunteers who help with interpretation. The hospital said any Cambodians currently receiving treatment at its inpatient ward will be subject to area restrictions. Like some other hospitals in border provinces, the healthcare services at Sunprasitthiprasong -- a well-known regional hospital -- are popular among Cambodians living along the border, given their high quality. It should be noted that the patients pay higher medical fees for treatment in the SMC ward. It is no secret that those higher up on the social ladder prefer to seek medical care at expensive private hospitals in Bangkok -- at least until the recent armed conflict broke out between Thailand and Cambodia. Cambodian strongman Hun Sen, at the beginning of the conflict that stemmed from a clash on May 28 in the Chong Bok area of Ubon Ratchathani's Nam Yuen district, called for his compatriots to stop seeking medical services in Thailand. This was part of the country's anti-Thai campaign as border checkpoints were closed one after another. Sunpasitthiprasong Hospital said its decision will affect only new patients, whereas former or current patients can continue their treatment. It did not mention emergency cases, but it's understood that the new rule will also apply to them. Such a decision seems to respond to noisy calls by some ultra-nationalist citizens -- as well as netizens engaging in wars of words -- over the past weeks amid the escalating armed conflict, that hospitals should stop serving Cambodian patients. Apparently, these narrow-minded racists misunderstand the nature of the SMC and the 30-baht healthcare scheme. Needless to say, this policy will be played up by Cambodian media channels to cast Thailand in a bad light. There are reports that the government and the Ad Hoc Centre for Thailand-Cambodia Border Situation gave a vague instruction to the hospital that it should adhere to the universal healthcare principle. The government must prohibit the hospital and other healthcare dispensers from adopting any policies based on racism. After all, such discrimination is not acceptable. Breaching human rights principles will do more harm than good to Thailand's image and reputation. Such discrimination resulting from racism will unnecessarily fuel hatred among the peoples of the two countries, making reconciliation even harder. Sunpasitthiprasong Hospital must not place itself in the middle of this conflict between the two governments. It must immediately review this racist policy, and not forget the mantra that sympathy must prevail for those in need of healthcare.
Bangkok Post
a day ago
- Bangkok Post
Novo Nordisk Completes Landmark Diabetes Affordability Project
Bangkok, - Novo Nordisk Pharma (Thailand) Ltd. (Novo Nordisk) today announced the successful completion of the Affordability Project in Thailand as part of its ongoing commitment to drive change in diabetes in the country. This transformative initiative was launched in collaboration with the Department of Medical Services, Ministry of Public Health. Over the past three years, the project has actively addressed the rising diabetic problems in Thailand through a public-private partnership with the Thai state-owned Rajavithi Hospital, Institute of Medical Research & Technology Assessment and Bureau of Medical System Supervision as the project's main implementor. Diabetes is a serious chronic disease with a prevalence rate of 10.2 percent in adults in Thailand, and the number of people living with diabetes rose by 300,000 in 2023. To compound the issue, there are many unmet needs as almost 14 percent of those diagnosed are not being treated. The three-year Affordability Project therefore focused on enhancing access to quality care, improving diagnostic measures, and training healthcare professionals (HCPs) across the nation. The project's highlights include: Screening success: The project has screened 53,000 individuals across 13 health zones in 21 provinces, exceeding initial targets and broadening diabetes detection efforts in underserved populations. HCPs training: A total of 7,000 HCPs were trained, aimed at adopting effective diabetes management practices. This training reached more than 2,200 hospitals nationwide, including practical workshops tailored to enhance patient care with more than 15,000 patients who received care from trained HCPs to help control their average blood sugar (HbA1c) levels. Glucose Control Initiative: The intensive glucose control programme enrolled 5,000 people living with diabetes, achieving remarkable results. Almost 70 percent of them reduced their HbA1c levels in every visit, with 28 percent reaching their treatment goals. Dr Taweesilp Visanuyothin, MD, Director-General of the Department of Medical Services, Ministry of Public Health, stated: 'Healthcare professionals have always been central to the effective treatment of diseases that require integrated care, such as diabetes. The Affordability Project is an example of how the public sector can collaborate with our partners in the private sector to enhance expertise for better patient care.' Dr Jinda Rojanamatin, MD, Director of Rajavithi Hospital, remarked: 'Rajavithi Hospital has been the primary institution to implement the project over the past three years. With our resources and expertise, the hospital has integrated the treatments for cardiovascular diseases and other non-communicable diseases (NCDs), including diabetes.' Ms Selina Christodoulakis, Director of Market Access and Public Affairs at Novo Nordisk Thailand, emphasised the rationale behind the project: 'Through the Affordability Project, we have made significant strides in making diabetes care more accessible and effective for the Thai population. By partnering with stakeholders across health systems in public sector to build integrated diabetes solutions that support healthcare professionals and improve the lives of people living with diabetes, we are collectively driving change for better health outcomes in Thailand.' With diabetes estimated to cost the Thai economy more than 375 billion THB, accounting for over 2.2 percent of the Thai GDP, the impact of the project transcends improved health outcomes. Effective blood glucose control has been linked to a reduction in severe complications related to diabetes, which can ultimately lead to substantial long-term savings in Thai healthcare costs. The event also featured the Cardio-Renal-Metabolic Clinic (CRM) at Rajavithi Hospital, aimed at elevating the standards of integrated care for NCDs, including the complications of obesity, diabetes, and other cardiovascular diseases. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube.
